Experts say that surgical robots or robot doctors will be conducting one in three operations in the US in the next five years. The surgical robots are estimated to multiply two folds by 2021, with surgeons guiding mechanical them on comp…
Complete report $3,850. DataPack (test volumes, sales forecasts, supplier shares) $2,500.
The report provides an overview of the cell surface marker testing in Europe (France, Germany, Italy, Spain, UK), including 5-year forecasts for CD4, CD8, CD34 and other markers by country.
The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies. During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in five European countries, including clinical significance and current laboratory practice, as well as five-year test volume forecasts by country and market segment.
The report examines market applications of monoclonal antibodies, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
Contains 125 pages and 24 tables